EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Redox environment modulates aggregation of ataxin‐3 in vitro — Implications for drug screening of cysteine‐rich proteins

Martyna Podlasiak, Martina Sollazzo, Elisa Monaca, Raffaele Sabbatella, Maria Agnese Morando, Oleg Chertkov, Laura Puglisi, Martina Mascellino, Anna Fricano, Sandra Macedo-Ribeiro, Caterina Alfano iD

The FEBS Journal · 2026

DOI: 10.1111/febs.70426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2026. Verfasst von Martyna Podlasiak und 10 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal. Hauptthemen laut MEDLINE: Ataxin-3, Cysteine, Protein Aggregation, Pathological, Repressor Proteins. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinocerebellar ataxia type 3 is a debilitating neurodegenerative disorder driven by the pathological aggregation of ataxin‐3 (Atx3), a deubiquitinating enzyme with a cysteine‐rich catalytic domain and an expandable polyglutamine (polyQ) tract. While the role of polyQ expansion in Atx3 aggregation is well documented, the influence of redox conditions on its self‐assembly remains underexplored. Here, we demonstrate that reducing agents and a redox environment critically modulate Atx3 aggregation by regulating disulfide bond formation within the Josephin domain. We demonstrate that dithiothreitol (DTT), through progressive oxidation, promotes the formation of non‐native and disulfide‐linked conformers, which may serve as nucleation centers for fibril formation. In contrast, tris(2‐carboxyethyl)phosphine preserves cysteine residues of Atx3 in the reduced state and inhibits aggregation, but concomitantly promotes cleavage of full‐length Atx3. Furthermore, we identify a previously underappreciated role for 4,5‐dihydroxy‐1,2‐dithiane, the DTT oxidation product, in directly triggering Atx3 aggregation. We also demonstrate that running aggregation assays at 50 °C circumvents the redox dependency of Atx3 aggregation, thereby streamlining the aggregation process and enabling the use of a simplified, robust platform for medium‐ to high‐throughput screening of aggregation modulators. These findings provide new insights into the redox‐dependent modulation of Atx3 aggregation and highlight critical considerations for in vitro aggregation assays of cysteine‐rich proteins, with broad implications for therapeutic strategies targeting cysteine‐rich, aggregation‐prone proteins in neurodegenerative diseases. Although our study focuses on in vitro investigation, it suggests that redox dysregulation in cells could promote pathogenic aggregation of Atx3, reinforcing the link between cellular redox balance and polyglutamine disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxin-3CysteineProtein Aggregation, PathologicalRepressor ProteinsOxidation-ReductionHumansProtein AggregatesDithiothreitolPeptidesDrug Evaluation, PreclinicalDisulfidesMachado-Joseph DiseasePhosphines

Stichwörter der Autor:innen

SCA3ataxin‐3neurodegenerationpolyglutamine diseasesprotein aggregationredox‐dependent aggregation

Substanzen

Ataxin-3CysteineATXN3 protein, humanProtein AggregatesDithiothreitolPeptidestris(2-carboxyethyl)phosphineDisulfidespolyglutamineRepressor Proteins

Autor:innen und Institutionen

  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
  • IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Portugal.
  • ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal.
  • Structural Biology and Biophysics Unit, Fondazione Ri.MED, Palermo, Italy.
  • Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Italy.
  • Department of Physics and Chemistry Emilio Segrè (DiFC), University of Palermo, Italy.

ORCID-Profile: Caterina Alfano

Förderung

  • Italian Ministry of University and Research

Zitieren

APA

Podlasiak, M., Sollazzo, M., Monaca, E., Sabbatella, R., Morando, M. A., Chertkov, O., Puglisi, L., Mascellino, M., Fricano, A., Macedo-Ribeiro, S., & Alfano, C. (2026). Redox environment modulates aggregation of ataxin‐3 in vitro — Implications for drug screening of cysteine‐rich proteins. The FEBS Journal. https://doi.org/10.1111/febs.70426

Vancouver

Podlasiak M, Sollazzo M, Monaca E, Sabbatella R, Morando MA, Chertkov O, et al. Redox environment modulates aggregation of ataxin‐3 in vitro — Implications for drug screening of cysteine‐rich proteins. The FEBS Journal. 2026. doi:10.1111/febs.70426

BibTeX
@article{Podlasiak2026,
  author = {Podlasiak, Martyna and Sollazzo, Martina and Monaca, Elisa and Sabbatella, Raffaele and Morando, Maria Agnese and Chertkov, Oleg and Puglisi, Laura and Mascellino, Martina and Fricano, Anna and Macedo-Ribeiro, Sandra and Alfano, Caterina},
  title = {Redox environment modulates aggregation of ataxin‐3 in vitro — Implications for drug screening of cysteine‐rich proteins},
  journal = {The FEBS Journal},
  year = {2026},
  doi = {10.1111/febs.70426}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche